{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:13:43Z","timestamp":1792653223602,"version":"4.5.0"},"reference-count":37,"publisher":"Society of Nuclear Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.2967\/jnumed.117.191718","type":"journal-article","created":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T00:48:12Z","timestamp":1496796492000},"page":"1852-1857","source":"Crossref","is-referenced-by-count":95,"title":["In Vivo Imaging of the Programmed Death Ligand 1 by <sup>18<\/sup>F PET"],"prefix":"10.2967","volume":"58","author":[{"given":"Dinko E.","family":"Gonz\u00e1lez Trotter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"McQuade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Rubins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Klimas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhizhen","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett M.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia J.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey S.","family":"O\u2019Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-An","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista L.","family":"Getty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Fayadat-Dilman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"Wahlberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Widmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Ekblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik Y.","family":"Frejd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Hostetler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Evelhoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2017,6,6]]},"reference":[{"key":"2021051712111587000_58.11.1852.1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3271"},{"key":"2021051712111587000_58.11.1852.2","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2016","journal-title":"N Engl J Med."},{"key":"2021051712111587000_58.11.1852.3","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2015","journal-title":"Lancet."},{"key":"2021051712111587000_58.11.1852.4","doi-asserted-by":"publisher","DOI":"10.4161\/onci.23661"},{"key":"2021051712111587000_58.11.1852.5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1630"},{"key":"2021051712111587000_58.11.1852.6","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.12"},{"key":"2021051712111587000_58.11.1852.7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2137"},{"key":"2021051712111587000_58.11.1852.8","doi-asserted-by":"publisher","DOI":"10.2174\/1874471011104020131"},{"key":"2021051712111587000_58.11.1852.9","first-page":"1962","article-title":"124I-Labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice","volume":"44","author":"Sundaresan","year":"2003","journal-title":"J Nucl Med."},{"key":"2021051712111587000_58.11.1852.10","first-page":"1412","article-title":"Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer","volume":"45","author":"Divgi","year":"2004","journal-title":"J Nucl Med."},{"key":"2021051712111587000_58.11.1852.11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3389\/fphar.2016.00131","article-title":"Immuno-positron emission tomography with zirconium-89-labeled monoclonal antibodies in oncology: what can we learn from initial clinical trials?","volume":"7","author":"Jauw","year":"2016","journal-title":"Front Pharmacol."},{"key":"2021051712111587000_58.11.1852.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2010.04.014"},{"key":"2021051712111587000_58.11.1852.13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.122465"},{"key":"2021051712111587000_58.11.1852.14","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-011-1810-4"},{"key":"2021051712111587000_58.11.1852.15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.111.093047"},{"key":"2021051712111587000_58.11.1852.16","doi-asserted-by":"crossref","unstructured":"Strand J Honarvar H Perols A . Influence of macrocyclic chelators on the targeting properties of 68Ga-labeled synthetic affibody molecules. PLoS One. 2013;42:446\u2013454.","DOI":"10.1371\/journal.pone.0070028"},{"key":"2021051712111587000_58.11.1852.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.131243"},{"key":"2021051712111587000_58.11.1852.18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.109.073239"},{"key":"2021051712111587000_58.11.1852.19","doi-asserted-by":"publisher","DOI":"10.7150\/thno.13502"},{"key":"2021051712111587000_58.11.1852.20","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.409"},{"key":"2021051712111587000_58.11.1852.21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2660"},{"key":"2021051712111587000_58.11.1852.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596"},{"key":"2021051712111587000_58.11.1852.23","doi-asserted-by":"publisher","DOI":"10.1038\/nri2326"},{"key":"2021051712111587000_58.11.1852.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"2021051712111587000_58.11.1852.25","doi-asserted-by":"publisher","DOI":"10.1038\/nature13904"},{"key":"2021051712111587000_58.11.1852.26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ctrv.2016.11.007","article-title":"Resistance to PD1\/PDL1 checkpoint inhibition","volume":"52","author":"O\u2019Donnell","year":"2017","journal-title":"Cancer Treat Rev."},{"key":"2021051712111587000_58.11.1852.27","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3477"},{"key":"2021051712111587000_58.11.1852.28","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-2141"},{"key":"2021051712111587000_58.11.1852.29","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.177493"},{"key":"2021051712111587000_58.11.1852.30","doi-asserted-by":"publisher","DOI":"10.7150\/thno.15253"},{"key":"2021051712111587000_58.11.1852.31","doi-asserted-by":"crossref","first-page":"203601","DOI":"10.1155\/2014\/203601","article-title":"Zirconium-89 labeled antibodies: a new tool for molecular imaging in cancer patients","volume":"2014","author":"van de Watering","year":"2014","journal-title":"Biomed Res Int."},{"key":"2021051712111587000_58.11.1852.32","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-007-0658-0"},{"key":"2021051712111587000_58.11.1852.33","doi-asserted-by":"publisher","DOI":"10.1021\/bc100137x"},{"key":"2021051712111587000_58.11.1852.34","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.113563"},{"key":"2021051712111587000_58.11.1852.35","doi-asserted-by":"publisher","DOI":"10.1021\/bc400343r"},{"key":"2021051712111587000_58.11.1852.36","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1646-3"},{"key":"2021051712111587000_58.11.1852.37","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.bbrc.2016.12.156","article-title":"Rapid PD-L1 detection in tumors with PET using a highly specific peptide","volume":"483","author":"Chatterjee","year":"2017","journal-title":"Biochem Biophys Res Commun."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.117.191718","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T20:20:03Z","timestamp":1621282803000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.117.191718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,6]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,11,1]]},"published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.2967\/jnumed.117.191718"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.117.191718","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,6]]}}}